Our leadership

Paul Meister is a partner in Novalis LifeSciences – a life science focused venture firm and is co-founder, and CEO of Liberty Lane Partners, LLC, a private investment company with investment holdings in healthcare, technology, and distribution-related industries. From 2014 to 2018, Mr. Meister was President of MacAndrews & Forbes Incorporated, a private company that owns or controls a diverse set of businesses. During 2018, Mr. Meister also served, on an interim basis, as Executive Vice Chairman of Revlon, Inc. a leading beauty products company, and acted as Revlon’s principal executive officer. From 2010 to 2014, Mr. Meister served as Chairman and CEO of inVentiv Health (now Syneos Health), a leading provider of commercial, consulting, and clinical research services to the pharmaceutical and biotech industries. Mr. Meister was Chairman of Thermo Fisher Scientific, Inc., a scientific instruments equipment and supplies company from November 2006 to April 2007. He was previously an executive officer of Fisher Scientific International, Inc., a predecessor of Thermo Fisher Scientific, Inc., from 1991 to 2006. Mr. Meister holds a Bachelor of Arts degree from the University of Michigan and a Master of Business Administration from Northwestern University. He currently serves as a director on the boards of Aptiv PLC, Quanterix Corporation, Oaktree Acquisition Corp II. He previously served as director of vTv Therapeutics and LKQ Corporation until 2018 and as a director of Revlon until 2019, and Scientific Games Corporation until 2020.

Chirag Patel has served as Co-Chief Executive Officer, President and director of the Company since August 2019. Mr. Patel served as a Co-Chairman of the Board from May 2018 to August 2019, and previously was Co-Founder of Amneal and served as Co-Chairman and Co-Chief Executive Officer of Amneal from 2005 until the combination with Impax Laboratories in 2018. With his brother, Chintu Patel, Mr. Patel has also invested in several independent biopharmaceutical companies including Asana Biosciences, Kashiv Biosciences and Prolong Pharmaceuticals, each of which specializes in innovative science and drug delivery technologies. Earlier in his career, Mr. Patel co-founded technology companies NextGen Technologies and Veriprise Wireless. In 2022, Mr. Patel served as the Chair of the Association for Accessible Medicines (AAM) Board of Directors. He continues to serve as an inaugural member of the CEO Advisory Committee for the International Generic and Biosimilar Medicines Association (IGBA). Mr. Patel also serves as a Managing Trustee for the Liberty Science Center of New Jersey and a Trustee for the Foundation for Morristown Medical Center. He is a recipient of the Ernst & Young National Entrepreneur of the Year® 2011 Life Sciences Award. Mr. Patel supports various philanthropic causes and, together with his wife, Priti Patel, established the Niswarth International Foundation in 2013. The Foundation aims to bring fresh water, sanitation, nutrition and education to underprivileged children. Mr. Patel received his bachelor’s degrees in Commerce from H.A. College of Commerce, India, and in Business Administration from New Jersey City University. He also holds an honorary Doctorate of Humane Letters from New Jersey City University in recognition of his efforts to serve others.

Chintu Patel has served as Co-Chief Executive Officer and director of the Company since August 2019. Mr. Patel served as a Co-Chairman of the Board from May 2018 to August 2019, and previously served as Co-Chairman and Co-Chief Executive Officer of Amneal from 2002 until the combination with Impax Laboratories in 2018. With his brother, Chirag Patel, Mr. Patel also co-founded and invested in several independent biopharmaceutical companies including Asana Biosciences, Kashiv BioSciences and Prolong Pharmaceuticals, each of which specializes in innovative science and drug delivery technologies. Before founding Amneal, Mr. Patel was a pharmacist and senior-level manager with Eckerd Pharmacy from 1994 to 2002, where he won numerous awards. Mr. Patel has been a featured speaker at the Hauppauge Industrial Association in New York and serves on the boards of the Long Island Association, Long Island University, and is a recipient of the Ernst & Young National Entrepreneur of the Year® 2011 Life Sciences Award. Mr. Patel and his wife, Falguni Patel, run the Irada International Foundation, which focuses on health, education, and community outreach projects in India and the United States. Mr. Patel holds a bachelor’s degree in Pharmacy from Rutgers College of Pharmacy. He also holds an honorary Doctor of Science degree from Long Island University Pharmacy in recognition of his contributions toward quality, integrity and innovation in pharmaceuticals.

Tasos is responsible for leading Amneal’s global finance strategies, including oversight for Finance and Accounting, Internal Audit, Investor Relations and Information Technology. He brings more than 30 years of corporate finance and leadership experience, including in the pharmaceutical and business analytics/data industries. Tasos most recently served as Alcresta Therapeutics, Inc.’s Chief Financial Officer from 2016 to 2020, where he led the company’s finance, corporate development, information technology and human resources functions, and was instrumental in supporting the commercialization of a novel therapy to help critically ill patients and expand the company’s R&D pipeline. Prior to that, he served as Executive Vice President, Chief Financial Officer and Head of Corporate Development of Ikaria, Inc., from 2011 to 2015. In that role, he led finance and corporate development functions in delivering robust global organic growth as well as growth through licensing and acquisitions. Before joining Ikaria, Tasos served as Senior Vice President and Chief Financial Officer of Dun & Bradstreet Corporation for seven years, and previously held financial and general management roles of increasing responsibility at Schering-Plough Corporation, Pharmacia Corporation, Novartis Corporation and Bristol-Myers Squibb. He currently serves as a Director on the boards of Kadmon Holdings and Zep Inc. He holds a B.S. in Mathematics and Finance from Gwynedd Mercy University and an M.B.A. from Drexel University.

Nikita leads Amneal’s Human Resources, Internal Communications and Corporate Social Responsibility functions. She also partners with the Co-CEOs to lead the creation and execution of the company’s long-term Corporate Strategy. Nikita joined Amneal in January 2014 as Senior Vice President, Human Resources & Corporate Affairs, and has served roles of increasing responsibility as a member of the company’s executive leadership team. Prior to joining Amneal, Nikita led the internal audit and human resources functions for Warner Chilcott, then a global specialty pharmaceutical company. She also supported corporate M&A, process improvements and systems efficiencies across the organization. Prior to Warner Chilcott, Nikita held leadership roles at AT&T and Deloitte. She holds a master’s degree in accounting and auditing from Gujarat University, India and is a certified public accountant.

Jason Daly has served as our Executive Vice President, Chief Legal Officer and Corporate Secretary since March 2025. Prior to that time, Mr. Daly served as our Senior Vice President, Chief Legal Officer and Corporate Secretary since January 2022. Mr. Daly is responsible for leading Amneal’s global legal and corporate compliance strategies with a focus on creating value for Amneal as it pursues its mission of delivering high-quality, affordable medicines to the U.S. and select international markets. He brings substantial experience leading the legal and commercial strategies for global pharmaceutical and medical device companies, including Teva Pharmaceuticals, Inc., where he held various roles, including Senior Vice President, U.S. Market Access and General Counsel – U.S. Generics & North American Commercial. Prior to Teva, Mr. Daly served nearly a decade in various legal and international commercial leadership roles with The Straumann Group, a Swiss medical device company. He has worked in private practice and was a law clerk to the Hon. Mary Lisi in the United States District Court in Rhode Island. Mr. Daly holds degrees from the University of Pennsylvania Law School and the University of Rhode Island, and is licensed to practice law in New Jersey, Massachusetts, and Rhode Island. He also holds professional certificates from The Kellogg School of Management, The Wharton School of Business, and The Boston University School of Management.

Greg is responsible for identifying, evaluating and executing transactions that align with the strategic vision of the company, including partnerships, in- and out-licensing agreements and mergers & acquisitions (M&A). He joined Amneal from Tarsadia Investments, where he most recently served as Portfolio Manager, Healthcare/Crossover Strategy, managing the firm’s public equities focused on small-and mid-cap companies in life sciences. Greg has also previously served as a Vice President at Tarsadia with responsibilities for M&A, where he led several acquisitions for the firm’s portfolio of companies. Greg began his career on Wall Street at Lazard Frères & Co. as an analyst in M&A advisory. Greg holds a master’s degree in International Relations and Economics and a bachelor’s degree in Economics and International Studies, both from Johns Hopkins University

Andy is focused on accelerating the sales, marketing and distribution of our evolving generics portfolio. Andy most recently served as President and CEO of North America Generics, Teva Pharmaceuticals, Inc. Prior to joining Teva, Andy was Senior Vice President of Sales and Marketing for the U.S. Generics Division at Allergan plc (formerly, Actavis plc; formerly, Watson Pharmaceuticals, Inc.) since September 2006. He joined then Watson in 1998 as Associate Director of Marketing in Generics. Before joining Watson, Andy served as National Accounts Manager for Lederle/American Cyanamid as well as Marketing Manager for Barr Laboratories. He serves as a Director of the Association for Accessible Medicines. Andy received his Bachelor’s degree in Business Administration and Management from State University of New York at Albany.

Joe has top-level leadership responsibility for all areas of our Specialty Commercial organization, including sales, marketing, market access and commercial operations. He has over 30 years of Pharma/BioTech and leadership experience. Prior to joining Amneal in April 2023, he served as Chief Commercial Officer, Senior Vice President at Halozyme, an American biotech company that develops novel oncology/HIV therapies and commercial testosterone products. In this role, Joe led the sales, marketing, operations/analytics, market access and all commercial functions. Prior to Halozyme, Joe served as VP, U.S. Sales Autoimmune & Rare Disease, Mallinckrodt Pharmaceuticals. He also served in numerous senior leadership roles at Novo Nordisk, Inc. including VP, U.S. Sales Biopharmaceutical Division, Marketing Brand Director for Women’s Health Products, and Head of their Sales Operations & Analytics Dept (which included Market Research, Forecasting, IC). Additionally, he held several other roles including Market Access Account Manager, Operations Lead, Director of L&D, Manager of Strategic Alliances and various leadership roles at Pfizer and Pharmacia Corporation. Joe started his career as a Primary Care Sales Specialist at The Upjohn Company. Joe holds a Bachelor of Science degree from The Pennsylvania State University in Accounting with an emphasis in Physiology and leadership certifications from the Wharton School of The University of Pennsylvania and Institute of Professional Excellence in Coaching.

Dr. Kone has leadership responsibility for Amneal’s Generic Research & Development activities, including overseeing the company’s global Complex Pharmaceutical Dosage Development, Regulatory Affairs and Portfolio and Project Management activities. He brings substantial R&D experience to Amneal and has served roles of increasing responsibility since joining the company in 2005. During his tenure, Dr. Kone has contributed significantly to the expansion of Amneal’s technical capabilities across new dosage forms, including leading the development of advanced programs in complex generic liquids, nasal sprays, topicals, transdermals, ophthalmics and inhalation. He has also played a key role in implementing innovative regulatory strategies that resulted in the delivery of several first-to-file and first-to-market opportunities and is deeply experienced in product lifecycle management. Prior to joining Amneal, Dr. Kone held R&D leadership roles for Zydus and Sun Pharmaceuticals. Dr. Kone received his Ph.D in Pharmacy from Andhra University, holds several patents and his research has been published in several journals of international acclaim.

Dr. Desai leads the expansion of Amneal’s Specialty pipeline, including overseeing clinical development activities and Medical Affairs operations supporting in-development and launched products. He brings more than 25-years of experience in pharma/biotech clinical development (Phase I to IV) as well as deep expertise in U.S. and Global Medical Affairs and life cycle management. Dr. Desai joins Amneal from Actinium Pharmaceuticals, Inc. where he served as Chief Medical Officer. Prior to that, he was Vice President, U.S. Medical Affairs, Oncology for GlaxoSmithKline, and successfully led the creation of launch readiness plans for four indications of three novel oncology products. Dr. Desai’s career also includes several years at Janssen where he helped lead the creation and execution of the company’s oncology pipeline. He also previously held senior medical affairs and clinical research leadership roles for Eli Lilly & Company; Takeda, Inc.; Eisai, Inc. Dr. Desai holds a Doctor of Medicine degree as well as a Bachelor of Medicine and Bachelor of Surgery (MBBS) degree from B.J. Medical College and Civil Hospital in Ahmedabad, India. His work is widely published in several prominent medical and scientific journals around the world.

Sanjay has oversight for all aspects of Amneal’s global Quality operations. He has extensive experience managing Quality, Operations, and Validation as well as Regulatory audits originating from the USFDA, MHRA, EU, TGA, Anvisa, MCC and Health Canada. Previously, Sanjay served as President, India Operations, with oversight for Amneal India operations, including managing the overall productivity and quality deliverables. Prior to joining Amneal, Sanjay held Quality and Operations positions at Ranbaxy Laboratories, Zydus Cadila, Torrent Pharmaceuticals, Cadila Pharmaceuticals, Intas Pharmaceuticals, Bharat Parenterals and Mesco Pharmaceuticals. He has developed quality systems, implemented various process improvement projects, developed and audited API vendor sites across the globe and successfully faced regulatory audits of various regulatory agencies multiple times. Sanjay is a member of the International Society for Pharmaceutical Engineering (ISPE) and Parenteral Drug Association (PDA and an accomplished speaker at various international conferences. He holds a degree in Pharmacy, a post graduate degree in Quality Management (Masters in Science, Quality Management), and Ph.D. in Operation Management.

Pranav leads Amneal’s global direct and indirect procurement strategies, with a focus on leveraging the company’s growing scale to drive cost-savings, boost efficiencies and enhance the value of goods/services we receive from vendors and partners. Pranav joined Amneal in 2005 to help build what was then a fledgling company. He quickly advanced his career into various leadership capacities, including previous roles as Global Director of Purchasing and most recently Vice President, Strategic Sourcing & Supply Management. His expertise in procurement has been instrumental to Amneal’s acquisitions of key assets in US and India as well as the launch of several first-to-market products. Pranav has nearly 20 years of experience and deep relationships across the global pharmaceutical industry. He holds an MBA from the University of Houston.

Sandeep leads all aspects of our India and Ireland-based operations, including manufacturing, projects & engineering, EHS and administrative services. Sandeep is a deeply experienced operations executive with more than 28 years of expertise, including a specialized focus on automation and digitization. He joins Amneal from Mumbai-based Cipla Ltd., where he most recently served as Executive Vice President, Head International Operations & CMG, responsible for 13 of the company’s manufacturing plants. Over his tenure with the company, Sandeep was instrumental in leading the automation, digitization and simplification project resulting in a touchless factory model that earned the Lighthouse Accreditation from the World Economic Forum in 2022. Prior to joining Cipla, Sandeep served as Senior Vice President, Biologics and Pharma OSD & Injectables for Wockhardt; as a Managing Director for Cipla Biotech; and as a Senior Production Executive for Intas Pharmaceuticals Ltd. He holds a Master of Business Administration and a Bachelor of Pharmacy from Pune University.

Maryll leads the company’s efforts to develop top-level regulatory strategies supporting the launch and commercialization of key products across the specialty, biosimilar, and generic portfolios. She also leads Amneal’s government relations and public policy interface with state and federal policymakers in the legislative and executive branches. Maryll joined Amneal from FDA’s Center for Drug Evaluation & Research (CDER), where she most recently served as Director of the Office of Generic Drug Policy, overseeing all regulatory and policy matters in the Office of Generic Drugs’ generic drug program. She previously served FDA in various senior leadership roles in CDER and the Office of the Commissioner, and as Associate Chief Counsel for Drugs in FDA’s Office of Chief Counsel. Prior to joining FDA, Maryll served as an associate with Zuckerman Spaeder LLP, specializing in food and drug and criminal defense matters. She began her legal career at Willkie Farr & Gallagher LLP, and clerked for the United States District Court for the District of Columbia. Maryll holds a J.D. from New York University School of Law, an M.A. in English Literature from the University of Texas at Austin, and a B.A. from the University of Michigan in Afro-American and African Studies and English.

Upendra leads our commercial operations in India and Emerging Markets in Southeast Asia, Middle East and Africa. He is a seasoned pharmaceutical leader with over 25+ years of experience with a proven track record in strategic business management, navigating complex regulatory environments and fostering team growth. Most recently, he served as the Commercial Head & EVP at GSK India. During his tenure at GSK, he worked in leadership roles in Indonesia, Sri Lanka, and the Middle East, and successfully managed market expansions, regulatory challenges, and high-value portfolios. He holds a Post Graduate Programme in Management from Indian Institute of Management (IIM), Indore and a Bachelor’s in Science (Chemistry) from Sheth L.U.J. College of Arts & Sir M.V. College of Science, Mumbai.

Deb Autor is CEO of Autor Strategies LLC, a strategic health care consulting firm; a Board Director for Pardes Biosciences, Inc. (PRDS); and Chair of the Board of the FDA Alumni Association.  Ms. Autor has also served as a Scientific Advisory Council Member of the Centre for Innovation in Regulatory Science and as a Board Member of the Antimicrobial Resistance Industry Alliance, the United States Pharmacopoeia Quality Institute, and the Parenteral Drug Association.

From 2019-2021, Ms. Autor was Global Head of Regulatory Excellence at AstraZeneca, where she led regulatory operations, policy and intelligence for AstraZeneca submissions globally.  Before joining AstraZeneca, Ms. Autor served at Mylan N.V. from 2013-2019, where she was Head of Strategic Global Quality and Regulatory Policy and Head of Global Quality.

Ms. Autor was a senior leader at FDA from 2001-2013, most recently as Deputy Commissioner for Global Regulatory Operations and Policy where she oversaw all FDA inspections, criminal investigations and international operations for human and veterinary drugs, biologics, medical devices, tobacco and food.  Before that, Ms. Autor served as Director of the Office of Compliance of the Center for Drug Evaluation and Research, leading enforcement and policy making for compliance with all drug requirements, including drug approval; current good manufacturing practices (GMP); human subject protection and bioresearch monitoring (GCP); import and export; and recalls.  Before joining FDA, Ms. Autor was a Trial Attorney in the Office of Consumer Litigation of the U.S. Department of Justice, where she litigated civil and criminal cases on behalf of FDA.

Ms. Autor received a Juris Doctor, Magna Cum Laude, from Boston University School of Law and a Bachelor of Arts in Psychology from Columbia University, Barnard College.

Kevin Buchi served as Impax’s Interim President and Chief Executive Officer from December 2016 until March 27, 2017 and as member of the Impax board from November 2016 until the completion of the combination of Impax and Amneal. From August 2013 to December 2016, Mr. Buchi served as President and Chief Executive Officer and member of the board of directors of TetraLogic Pharmaceuticals Corporation (formerly NASDAQ: TLOG), a biopharmaceutical company (“TetraLogic Pharmaceuticals”), whose assets were subsequently acquired by Medivir AB in December 2016. Prior to TetraLogic Pharmaceuticals, Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), from October 2011 to May 2012. Prior to Teva, Mr. Buchi served as Chief Executive Officer of Cephalon, Inc. (formerly NASDAQ: CEPH), which was subsequently acquired by Teva, from December 2010 to October 2011, and held various positions at Cephalon including Chief Operating Officer from January 2010 to December 2010 and Chief Financial Officer from 1996 to 2009. Since April 2013, he has served as a director and member of the remuneration and nominating committee, and audit committee of the board of Benitec Biopharma Ltd. (NASDAQ: BNTC), a biotechnology company headquartered in Australia. Mr. Buchi has previously served on the board and committees of various pharmaceutical and biotechnology companies including: the board and the audit committee of EPIRUS Biopharmaceuticals, Inc. (formerly NASDAQ: EPRS) from June 2013 to July 2016; the board and compensation committee of Alexza Pharmaceuticals, Inc. (formerly NASDAQ: ALXA) from January 2013 to June 2016; the board and audit committee of Forward Pharma A/S (NASDAQ: FWP) from December 2012 to May 2016; the board and audit, compensation and nominating and corporate governance committees of Stemline Therapeutics, Inc. (NASDAQ: STML) from March 2012 to May 2016; and the board and audit committee of Meslobast Limited from 2010 to 2012. Mr. Buchi received his B.A. degree from Cornell University and a Masters of Management from the J.L. Kellogg Graduate School of Management at Northwestern University. Mr. Buchi’s extensive experience as a senior executive and board member in the pharmaceutical industry provides the board with unique insights into our business.

Jeff George has over 25 years of global healthcare and corporate leadership experience across North America, Europe, and emerging markets. He is currently the Managing Partner of Maytal Capital, a healthcare-focused private equity investment and advisory firm he founded in 2017. Between 2008 and 2016, he served on the Executive Committee of Novartis Group AG, one of the largest global pharmaceutical companies, first as Division Head and CEO of Sandoz, Novartis’ $10 billion generic pharmaceuticals and biosimilars subsidiary which is now publicly-listed, and then as Division Head and CEO of Alcon, Novartis’ then $10 billion branded eye care subsidiary which was spun out of Novartis in 2019 as an independent company (NYSE: ALC). In both roles, he was responsible for leading over 25,000 associates globally across more than 160 countries.

Mr. George previously headed Emerging Markets for the Middle East, Africa, Southeast Asia and CIS at Novartis Pharmaceuticals and served as Vice President and Head of Western and Eastern Europe for Novartis Vaccines. Prior to this, he held leadership roles at Gap Inc. and McKinsey & Co. Jeff currently serves as Chairman of the Board of Directors at LENZ Therapeutics (NASDAQ: LENZ), an ophthalmic biotech company, and as Chairman of Lykos Therapeutics, a late-stage clinical CNS-focused biopharma company. He also serves on the Board of Directors of 908 Devices (NASDAQ: MASS), a pioneer in life science diagnostics, and Dorian Therapeutics, a Silicon Valley-based cellular senescence biotech spun out of Stanford University, as well as on several non-profit boards. He holds an MBA from Harvard Business School, an M.A. from Johns Hopkins University’s School of Advanced International Studies (SAIS), and a B.A. from Carleton College.

John Kiely has more than 35 years of financial leadership and advisory experience serving public companies, including multi-national corporations. Until June 2019 he served as Senior Assurance Partner at Pricewaterhouse Coopers, where he focused on the pharmaceutical, manufacturing chemical and medical device sectors. Since 1980, he has held various roles of increasing responsibility at Pricewaterhouse Coopers, including as U.S. Pharmaceutical Leader, Global Pharmaceutical Assurance Leader, Private Equity Assurance Leader and Assurance Chief Quality Officer. Mr. Kiely currently serves on the board at Zovio, Inc.

Ted Nark has served as Managing Director of KRG Capital Partners, a Denver-based private equity fund currently investing a $2 billion fund, since 2007. In that role, Mr. Nark has led the identification, negotiation and due diligence of new acquisitions and has worked with portfolio companies and maintained relationships with limited partners. While at KRG, Mr. Nark has led the acquisition and successful monetization of companies including Convergint Technologies, Diversified Food Services and Petrochoice. From 2006 to 2007, Mr. Nark was a Partner at Leonard Green & Partners and from 2002 to 2006, he served as Chief Executive Officer and Chairman of the Board of White Cap Construction Supply, a Leonard Green-owned distributor of construction hardware, tools and materials to professional contractors in the United States. Previously, Mr. Nark served as Chief Executive Officer of Corporate Express Australia and Group President at Corporate Express Inc. Mr. Nark currently serves as Chairman of the Board of Convergint Technologies and Trafficware and is on the Board of Directors of Western Windows and The Maroon Group. Mr. Nark has previously served on the Boards of Corporate Express Australia, Fort Dearborn, White Cap Construction Supply, FTD, Leslies Pools, Gaiam, Real Goods Solar and Claim Jumper. Mr. Nark received a B.A. from Washington State University. Mr. Nark’s career in private equity and in executive positions will provide the Board with unique insight into management, challenges and opportunities.

Gautam Patel has served as Managing Director of Tarsadia Investments, a private investment firm based in Newport Beach, CA since 2012. In that role, Mr. Patel has led a team of investment professionals to identify, evaluate and execute principal equity investments across sectors including life sciences, financial services and technology. Prior to joining Tarsadia, Mr. Patel served as Managing Director at Lazard from 2008 to 2012, where he led financial and strategic advisory efforts in sectors including transportation and logistics, private equity, specialty pharmaceuticals and medical devices. Prior to that, Mr. Patel served in a variety of roles at Lazard from 1999 to 2008, including multiple restructuring, bankruptcy and corporate reorganization assignments. From 1994 to 1997, Mr. Patel was an Analyst at Donaldson, Lufkin & Jenrette (DLJ), where he worked on M&A as well as high-yield and equity financings. Mr. Patel is currently a Board Member of companies such as Amneal Pharmaceuticals, Adello Biologics, Asana Biosciences, LERETA and AIONX Antimicrobial Technologies, as well as Tarsadia Foundation. Mr. Patel received a B.A. from Claremont McKenna College, a B.S. from Harvey Mudd College, an M.S. from the London School of Economics (LSE) and an MBA from the University of Chicago. Mr. Patel’s extensive experience as an advisor, investor and operator in generics and the pharmaceutical industry broadly will provide the Board with insight regarding business development, strategic planning and operational management.

Shlomo Yanai has more than 15 years of corporate leadership experience, primarily in the pharmaceutical industry. He most recently served as President and CEO at Teva Pharmaceutical Industries Ltd., from 2007 to 2012, where he increased revenues from $8.4 billion in 2006 to $18.3 billion in 2011, and net profit from $1.9 billion to $4.4 billion over the same time period. Mr. Yanai also serves as an advisor to CVC Capital Partners, a leading private equity firm with $80.5 billion in assets under management. In addition, he currently serves on the boards of PDL BioPharma Inc. and WR Grace & Co. Mr. Yanai previously served on the boards of Cambrex Corp., Lumenis Ltd., Perrigo Company and Sageant Pharmaceuticals, among others, and held various leadership positions in the Israel Defense Forces.